Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bumexazole is a brand name for the combination antibiotic co-trimoxazole, which consists of sulfamethoxazole and trimethoprim. It is an anti-infective agent used to treat a wide range of bacterial infections, including those of the urinary tract, respiratory system, and gastrointestinal tract, as well as Pneumocystis jirovecii pneumonia. The drug works through a synergistic sequential blockade of bacterial folic acid synthesis: sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. This dual action effectively halts bacterial growth and replication by preventing the production of tetrahydrofolic acid, an essential precursor for nucleic acid synthesis. Bumexazole is marketed by Pharmacell Genomics and is available in various formulations, including tablets and oral suspensions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethoxazole + trimethoprim.